PRESSRELEASES

23 March, 2023

NEX-22 preclinical data shows controlled release of liraglutide for one month

Nanexa AB (publ) today announced positive outcome in the first preclinical study with NEX-22. In a one-month study in rats, single doses of two different PharmaShell® formulations were studied in different doses. The results show a controlled release of liraglutide, with plasma exposure over 28 days for NEX-22, compared to around 2 days for a formulation with liraglutide without the PharmaShell coating.

READ MORE

16 February, 2023

Nanexa publishes year-end report for 2022

Agreement and directed issue to Novo Nordisk, solution to patent infringement lawsuit and phase 1 study with NEX-20 started

READ MORE

LATEST REPORTS

PRESENTATIONS

2023-02-16

Webcast med Rapportkommentar, Bokslutskommuniké 2022

2023-01-31

Aktiespararna, Aktiedagen Lund, vd David Westberg presenterar

2022-12-07

ABGSC Investor Day, VD David Westberg presenterar

MEET NANEXA

Inga planerade träffar

PRENUMERERA